Relevance of systems pharmacology in drug discovery
Authors:
- Lourdes Cucurull-SanchezLCLourdes Cucurull-Sanchez
- Karen G. SpinkKSKaren G. Spink
- Sterghios Athanasios MoschosSMSterghios Athanasios Moschos
- 1 July 2012
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 17 (13-14) , 665-670
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- The problems with today's pharmaceutical business—an outsider's viewNature Biotechnology, 2011
- Optimising in vivo pharmacology studies—Practical PKPD considerationsJournal of Pharmacological and Toxicological Methods, 2010
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Proof of Concept: A PhRMA Position Paper With Recommendations for Best PracticeClinical Pharmacology & Therapeutics, 2010
- Assessing the translatability of drug projects: what needs to be scored to predict success?Nature Reviews Drug Discovery, 2009
- Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerationsDrug Discovery Today, 2009
- Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug DevelopmentClinical Pharmacokinetics, 2008
- Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker developmentDrug Discovery Today, 2007
- Translational medicine: can it really facilitate the transition of research “from bench to bedside”?European Journal of Clinical Pharmacology, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004